Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166
K Oba, H Konno, T Tanaka, M Baba, K Kamiya, M Ohta… - Cancer letters, 2002 - Elsevier
K Oba, H Konno, T Tanaka, M Baba, K Kamiya, M Ohta, T Kaneko, T Shouji, A Igarashi…
Cancer letters, 2002•ElsevierMMI-166 is a selective inhibitor of matrix metalloproteinase (MMP)-2 and MMP-9. Mice
implanted a human colon cancer orthotopically received 200 mg/kg of MMI-166 orally for 5
weeks. Gelatin zymography demonstrated that the administration of MMI-166 remarkably
decreased the active MMP-2 expression. Histological examination revealed that MMI-166
showed prominent effect on reduction of the invasive feature of the cancer cells and showed
inhibitory effect on tumor vasculature, resulting in the significant decrease of microvessel …
implanted a human colon cancer orthotopically received 200 mg/kg of MMI-166 orally for 5
weeks. Gelatin zymography demonstrated that the administration of MMI-166 remarkably
decreased the active MMP-2 expression. Histological examination revealed that MMI-166
showed prominent effect on reduction of the invasive feature of the cancer cells and showed
inhibitory effect on tumor vasculature, resulting in the significant decrease of microvessel …
MMI-166 is a selective inhibitor of matrix metalloproteinase (MMP)-2 and MMP-9. Mice implanted a human colon cancer orthotopically received 200 mg/kg of MMI-166 orally for 5 weeks. Gelatin zymography demonstrated that the administration of MMI-166 remarkably decreased the active MMP-2 expression. Histological examination revealed that MMI-166 showed prominent effect on reduction of the invasive feature of the cancer cells and showed inhibitory effect on tumor vasculature, resulting in the significant decrease of microvessel density of the implanted tumor and liver metastasis compared with the control group. Conclusively, MMI-166 is a potent antiangiogenic oral agent for a human colon cancer.
Elsevier